Vertex Pharmaceuticals to start phase 3 "REALIZE" trial with telaprevir in treatment-failure HCV patients.
D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D009842:Oligopeptides / Q000627:therapeutic use*; D017211:Treatment Failure
D009842:Oligopeptides; C486464:telaprevir